mAbxience Research S.L.

Quick facts

Phase 3 pipeline

• EU-approved Avastin® · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.
• EU-Opdivo® · Oncology
  EU-Opdivo® is a PD-1 checkpoint inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• MB09 (denosumab biosimilar) · Oncology, Bone Health, Rheumatology
  MB09 is a biosimilar of denosumab that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to suppress osteoclast formation and bone resorption.
• RTXM83 · Oncology
  RTXM83 is a monoclonal antibody targeting PD-L1.
• US- sourced Opdivo®
  Opdivo is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.

Phase 1 pipeline

• EU Source Enbrel
• EU-sourced Xgeva
• EU-Synagis®
• MB02
• MB02-DM
• MB02-SP
• MB04
• MB09
• US licenced Avastin®
• US License Enbrel
• US-sourced Xgeva
• US-Synagis®

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• mAbxience Research S.L. portfolio CI brief
• mAbxience Research S.L. pipeline updates RSS